These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30998679)

  • 21. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer.
    Lopez-Guerra JL; Verdugo-Sivianes EM; Otero-Albiol D; Vieites B; Ortiz-Gordillo MJ; De León JM; Praena-Fernandez JM; Marin JJ; Carnero A
    Oncotarget; 2015 Oct; 6(30):30343-56. PubMed ID: 26327509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.
    Langer R; Von Rahden BH; Nahrig J; Von Weyhern C; Reiter R; Feith M; Stein HJ; Siewert JR; Höfler H; Sarbia M
    J Clin Pathol; 2006 Jun; 59(6):631-4. PubMed ID: 16731604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.
    Bechert C; Kim JY; Tramm T; Tavassoli FA
    Virchows Arch; 2016 Dec; 469(6):659-667. PubMed ID: 27664050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
    Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma.
    Huber GF; Albinger-Hegyi A; Soltermann A; Roessle M; Graf N; Haerle SK; Holzmann D; Moch H; Hegyi I
    Cancer; 2011 Oct; 117(20):4659-70. PubMed ID: 21448927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
    Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
    Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer.
    Iwaya K; Tsuda H; Fukutomi T; Tsugane S; Suzuki M; Hirohashi S
    Jpn J Clin Oncol; 1997 Feb; 27(1):6-12. PubMed ID: 9070333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors.
    Dajti G; Serra M; Cisternino G; Ceccarelli C; Pellegrini A; Melina M; De Leo A; Santini D; Taffurelli M; Zanotti S
    Oncologist; 2024 May; 29(5):384-391. PubMed ID: 37995311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of p16 and pRB in invasive breast cancer.
    Shin E; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.